demeclocycline hydrochloride

Trade name: declomycin

Small moleculeapproved

Approved

Jan 14, 1960

Demeclocycline hydrochloride is an antibiotic isolated from a mutant strain of Streptomyces aureofaciens. It inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria. Demeclocycline has antimicrobial activity against a wide range of gram-negative and gram-positive organisms. Demeclocycline is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms. Demeclocycline is currently used to treat hyponatremia in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Demeclocycline mainly attenuates hyponatremia in SIADH by reducing adenylate cyclase 5/6 expression and, consequently, cAMP generation, AQP2 gene transcription, and AQP2 abundance in the renal inner medulla, coinciding with a reduced vasopressin escape response in other collecting duct segments. — NCATS

Clinical trial activity

7 trials · 4 clinical orgs · 8 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2013 (NCT01753856)

Timeline

1960s

Jan 14, 1960
Earliest FDA Approval
Jan 14, 1960
American Cyanamid — NDA Secondary Org
Nov 14, 1960
Lederle — First NDA Organization
Nov 14, 1960
Lederle — NDA Organization
Sep 22, 1964
Corepharma — NDA Secondary Org

2000s

Mar 22, 2004
Impax Laboratories — Marketing Organization
Dec 13, 2004
Barr Laboratories — Marketing Organization
Feb 27, 2008
Amneal Pharmaceuticals — Marketing Organization
Dec 1, 2008
Akorn, Inc. — Marketing Organization

2010s

Aug 18, 2015
Epic Pharma Llc — Marketing Organization
Jan 1, 2016
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2022
Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Bacterial 70S ribosomeINHIBITOR
Bacterial 70S ribosome inhibitor
16s RRNA

Approval history

approvedJan 14, 1960

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12

Mol. weight: 464.86 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Sources

Also known as

[4s-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide
[4s-(4alpha,4aalpha,5aalpha,6beta,12aalpha)]-7-chloro-4-(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide
6-demethyl-7-chlorotetracycline
6-demethyl-7-chlorotetracycline
7-chloro-6-demethyltetracycline
7-chloro-6-demethyltetracycline
declomycin
declomycin
declomycin
demeclociclina
demeclociclina
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline
demeclocycline hcl
demeclocycline hcl
demeclocycline hcl
demeclocycline hydrochloride
demeclocycline hydrochloride
demeclocycline hydrochloride
demeclocycline hydrochloride
demeclocycline hydrochloride
demeclocyclinum
demeclocyclinum
demethylchlortetracyclin
demethylchlortetracyclin
demethylchlortetracycline
demethylchlortetracycline
demethylchlortetracycline
demethylchlortetracycline
demethylchlortetracycline
demethylchlortetracycline hcl
demethylchlortetracycline hcl
dmct
dmct
dmctc
dmctc
ledermycin
ledermycin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06193408	Phase 2	Feb 11, 2024	—
NCT06566508	Phase 2/Phase 3 (Phase 3)	Nov 20, 2023	Mansoura University
NCT06466538	Phase 2/Phase 3 (Phase 3)	Jun 1, 2022	Mansoura University
NCT06453304	Phase 2/Phase 3 (Phase 3)	Mar 20, 2022	Mansoura University
NCT02740933	Phase 1	Apr 1, 2016	Harvard University
NCT03042377	Phase 4	Mar 1, 2015	Istanbul Medipol University
NCT01753856	Phase 4	Jan 1, 2013	Eli Lilly

Showing 7 of 7 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Mansoura University	Academic/Hospital	3	3	1	2022
Eli Lilly	For profit	1	1	1	2013
Harvard University	Academic/Hospital	1	1	1	2016
Istanbul Medipol University	Academic/Hospital	1	1	1	2015

4 organizations

Page 1 / 1

Marketing (8)

Organization	Org type	Relationship	Date
Akorn, Inc.	For profit	MKTG	Dec 1, 2008
American Cyanamid	For profit	NDA2	Jan 14, 1960
Amneal Pharmaceuticals	For profit	MKTG	Feb 27, 2008
Barr Laboratories	For profit	MKTG	Dec 13, 2004
Corepharma	For profit	NDA2	Sep 22, 1964
Epic Pharma Llc	For profit	MKTG	Aug 18, 2015
Impax Laboratories	For profit	MKTG	Mar 22, 2004
Lederle	For profit	NDA	Nov 14, 1960